For a group of patients subjected to preoperative radiochemotherapy for locally advanced rectal carcinoma, however,

there was no correlation between the level of Bax www.selleckchem.com/products/BAY-73-4506.html expression and tumor recurrence (56). Contrary to our findings, results of studies performed in vitro demonstrate that CRC cell lines with high Bax expression responded well to long-term 5-FU exposure, which induced Seliciclib chemical structure apoptosis (57),(58). Inhibitors,research,lifescience,medical Additionally, studies performed in vitro have indicated that antioxidants, such as N-acetylcysteine and vitamin E, are required to augment Bax expression to elicit 5-FU-induced apoptosis (59). Nevertheless, there were no such findings in clinical studies or in experimental studies Inhibitors,research,lifescience,medical performed in vivo. Based on our findings, however, the low levels of Bax may exert less intrinsic resistance to the complex cascade of intracellular signals of apoptotic pathways triggered by chemotherapeutic agents. Thus, there are apparently distinct mechanisms of Bax involvement in the manifestation of apoptosis. Molecular markers have different functional roles, similar to the Bax expression observed here. A recent investigation by Tsuji et al (60) demonstrated that high expression of dihydropyrimidine dehydrogenase (DPD) in Stage II and III CRCs was an effective indicator Inhibitors,research,lifescience,medical of oral 5-FU-based adjuvant therapy; however, low expression of tumor DPD predicted poor survival for patients undergoing surgery Inhibitors,research,lifescience,medical alone. The prognostic

value of high Bax expression observed for the surgery-alone group might be useful for a sub-set of Stage I and Stage II patients; in contrast, the predictive

value of Bax expression might be useful in predicting the efficacy of 5-FU-based therapy, particularly for patients with advanced stage disease (Stage III or IV), who routinely receive 5 -FU-based adjuvant therapy. Larger studies determining the clinical usefulness of Bax expression in CRCs according to pathologic stage may confirm these findings. In the current investigation, increased Bcl-2 expression in CRCs Inhibitors,research,lifescience,medical was not predictive of 5 -FU-based adjuvant therapy; however, increased Bcl-2 expression was an indicator of prolonged survival for patients who had surgery alone. The prognostic value of Bcl-2 expression in CRCs has been demonstrated (8),(61). The association between increased Dacomitinib Bcl-2 expression and patient overall survival was stronger in early-stage CRCs (62)-(64) and for CRCs located in the distal colorectum (11). Similar to our findings, other studies demonstrated that, for patients receiving 5-FU-based chemotherapy, Bcl-2 expression did not influence response to chemotherapy and did not affect overall survival(55),(65),(66). Our multivariate survival analysis, however, demonstrated a better survival of patients whose tumors had low a Bax/Bcl-2 ratio (i.e., Bax was low) and who received 5-FU-based adjuvant chemotherapy. Furthermore, the expression of these two apoptotic markers was not associated with p53nac.